Skip to main content

Table 3 Diagnostic accuracy measures in non-contrast-enhanced MRI techniques and contrast-enhanced techniques in brain tumor imaging

From: Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging—a comprehensive overview

Clinical question

Diagnostic performance non-CE

Diagnostic performance CE gold standard

Author (year)

Astrocytic tumor grading

AUC 0.96 (95% CI 0.84–1.0) CBF ASL

AUC 0.98 (95% CI 0.87–1.00) CBF DSC

Morana et al. (2018)

Glioma grading

AUC 0.82 (95% CI 0.62–1.00) APTw mean, AUC 0.90 (95% CI 0.73–1.00) Cho/Cr MRS

AUC 0.65 (0.47–0.84) CE T1

Sakata et al. (2017)

Glioma grading

AUC 0.85–0.86 (95% CI 0.74–0.92 and 95% CI 0.75–0.94) APTw90

AUC 0.80–0.82 (95% CI 0.64–0.89 and 0.67–0.90) nCBV90 DSC

Park et al. (2015)

Pediatric posterior fossa grading

AUC 0.97 ADC (classification rate) DWI

AUC 0.84 CE T1 (classification rate)

Rodriguéz Gutierrez et al. (2014)

Discriminate between CNS lymphoma and GBM

AUC 0.94 ADC DWI

Equal rate of CE T1 contrast enhancement between groups

Ko et al. (2016)

Discriminate between CNS lymphoma and GBM

Accuracy 0.91 (95% CI 0.84–0.95) CBF ASL

Accuracy 93–95% conv MRI including CE T1

You et al. (2018)

Discriminate between metastases and CNS lymphoma/GBM

AUC 0.96 Lac/Cr MRS

AUC 0.97 PSRmax DSC

Vallée et al. (2018)

Progression vs pseudoprogression in GBM

AUC 0.84 (95% CI 0.72–0.96) linear anisotropy DTI

AUC 0.77 (95% CI 0.63–0.92) rCBVmax DSC

Wang et al. (2016)

Progression vs pseudoprogression in glial tumors and brain metastases

AUC 0.79 (95% CI 0.77–0.81) T2FLAIR

AUC 0.57 (± 0.08) CE T1

Tiwari et al. (2016)

Progression vs pseudoprogression in glioma

AUC 0.82 CBF ASL

AUC 0.84 nrCBV DSC

Wang et al. (2018)

Progression vs pseudoprogression in metastases

AUC 0.94-0.95 (95% CI 0.87–0.98 and 0.88-0.98) IVIM

AUC 0.91–0.93 (95% CI 0.83–0.96 and 0.86–0.98) DSC + DWI

Kim et al. (2014)

Progression vs pseudoprogression in GBM

AUC 0.89 APTw90

AUC 0.77 and 0.80 CBV DSC

Park et al. (2016)

Detection of cerebral metastasis

Sensitivity 0.80% FLAIR-EPI

Sensitivity 100% SE-T1W

Tomura et al. (2007)

  1. ADC apparent diffusion coefficient, ASL arterial spin labeling, AUC area under curve, CBF cerebral blood flow, CE contrast-enhanced, CNS central nervous system, conv conventional, DSC dynamic susceptibility weighted, DTI diffusion tensor imaging, DWI diffusion-weighted imaging, FLAIR fluid attenuated inversion recovery, GBM glioblastoma, IVIM intravoxel incoherent motion, MRS magnetic resonance spectroscopy, nrCBV normalized relative cerebral blood volume, PSR percentage of signal recovery, rCBVmax maximum relative cerebral blood volume